Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

Claim 1 (original): A crystalline form of the compound tris(hydroxymethyl)methylammonium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid of the formula (I) having an X-ray powder diffraction pattern with specific peaks at 2-theta = 3.2, 6.3, 9.5 and 11.0.

Claim 2 (currently amended): ~~A~~ The crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern with specific peaks at 2-theta = 3.2, 6.3, 9.5, 11.0, 12.0, 12.4, 13.9 and 21.5.

Claim 3 (currently amended): ~~A~~ The crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern with specific peaks at 2-theta = 3.2, 6.3, 9.5, 11.0, 12.0, 12.4, 13.9, 15.8, 21.5, 22.7, 23.6 and 24.9.

Claim 4 (original): A crystalline form of the compound tris(hydroxymethyl)methylammonium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid having an X-ray powder diffraction pattern with specific peaks at 2-theta = 6.9 and 13.1.

Claim 5 (currently amended): ~~A~~ The crystalline form as claimed in claim 4 having an X-ray powder diffraction pattern with specific peaks at 2-theta = 6.9, 13.1, 14.9 and 20.6.

Claim 6 (currently amended): ~~A~~ The crystalline form as claimed in claim 4 having an X-ray powder diffraction pattern with specific peaks at 2-theta = 6.9, 8.5, 9.0, 13.1, 14.9, 17.2, 18.2, 18.6, 19.0, 19.4, 20.6 and 25.4.

Claim ~~5~~7 (original): A pharmaceutical composition comprising a crystalline form as claimed in any one of the preceding claims, together with a pharmaceutically acceptable carrier.

Claim ~~6~~ 8 (currently amended): A process for the manufacture of a pharmaceutical composition comprising a crystalline form as claimed in claim 1 or claim 4, together with a pharmaceutically acceptable carrier ~~as claimed in claim 5~~ which comprises admixing ~~a~~ the crystalline form ~~as claimed in claim 1 or claim 4~~ together with ~~a~~ the pharmaceutically acceptable carrier.

Claim ~~7~~ 9 (cancelled).

Claim ~~8~~ 10 (currently amended): A method of treating type 2 diabetes, hypercholesterolemia, hyperlipoproteinemia or atherosclerosis ~~a disease condition wherein inhibition of HMG CoA reductase is beneficial~~ which comprises administering to a warm-blooded mammal in need thereof an effective amount of ~~a~~ the crystalline form as claimed in claim 1 or claim 4.

Claim ~~9~~ 11 (currently amended): A process for the manufacture of ~~a~~ the crystalline form as claimed in claim 1 or claim 4 which comprises forming crystals by:

a) slurrying a sample of amorphous tris(hydroxymethyl)methylammonium salt (1) in an organic solvent at a temperature below ambient temperature;

b) ~~filtration of~~filtering the resultant mixture; and

c) optionally drying ~~of~~ the resultant product ~~as necessary~~.

Claim ~~10~~ 12 (currently amended): A process ~~as claimed in claim 9~~ for the manufacture of ~~Form 2~~the crystalline form as claimed in claim 1 which comprises forming crystals by:

a) slurrying a sample of amorphous tris(hydroxymethyl)methylammonium salt (1) in an organic solvent at a temperature below ambient temperature;

b) filtering the resultant mixture; and

c) optionally drying the resultant product,

wherein the organic solvent is acetonitrile, ethyl acetate or MTBE (methyl t-butylether).

Claim ~~11~~ 13 (currently amended): A process for the manufacture of ~~a~~ the crystalline form as claimed in claim 4 ~~claim 9 for the manufacture of Form 3~~ which comprises forming crystals by:

a) slurrying a sample of amorphous tris(hydroxymethyl)methylammonium salt (1) in an organic solvent at a temperature below ambient temperature;

b) filtering the resultant mixture; and

c) optionally drying the resultant product,

wherein the organic solvent is isopropanol.

Claim ~~12~~ 14 (currently amended): ~~A~~ The process as claimed in claim 12 or claim 13 ~~any one of claims 9 to 11~~ wherein the temperature is about 0° C.